Evidence map›Paper›PMID 34855773›Full record

ArticlePloS one2021

High-dose drug heat map analysis for drug safety and efficacy in multi-spheroid brain normal cells and GBM patient-derived cells.

Sang-Yun Lee, Yvonne Teng, Miseol Son, Bosung Ku, Ho Sang Moon, Vinay Tergaonkar, Pierce Kah-Hoe Chow, Dong Woo Lee, Do-Hyun Nam

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sang-Yun LeeDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
Yvonne TengResearch & Development Department, AVATAMED Pte. Ltd., Singapore, Singapore.
Miseol SonResearch & Development Department, AVATAMED Pte. Ltd., Singapore, Singapore.
Bosung KuCentral R & D Center, Medical & Bio Device (MBD) Co., Ltd, Suwon, Republic of Korea.
Ho Sang MoonCentral R & D Center, Medical & Bio Device (MBD) Co., Ltd, Suwon, Republic of Korea.
Vinay TergaonkarLaboratory of NFκB Signaling, Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore.
Pierce Kah-Hoe ChowDivision of Surgery and Surgical Oncology, National Cancer Centre Singapore (NCCS), Singapore, Singapore.
Dong Woo LeeDepartment of Biomedical Engineering, Konyang University, Daejon, Korea.ORCID 0000-0003-4436-8272
Do-Hyun NamDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To test the safety and efficacy of drugs via a high does drug heat map, a multi-spheroids array chip was developed by adopting a micropillar and microwell structure. In the chip, patient-derived cells were encapsulated in alginate and grown to maturity for more than 7 days to form cancer multi-spheroids. Multi-spheroids grown in conventional well plates require many cells and are easily damaged as a result of multiple pipetting during maintenance culture or experimental procedures. To address these issues, we applied a micropillar and microwell structure to the multi-spheroids array. Patient-derived cells from patients with Glioblastoma (GBM), the most common and lethal form of central nervous system cancer, were used to validate the array chip performance. After forming multi-spheroids with a diameter greater than 100μm in a 12×36 pillar array chip (25mm × 75mm), we tested 70 drug compounds (6 replicates) using a high-dose to determine safety and efficacy for drug candidates. Comparing the drug response of multi-spheroids derived from normal cells and cancer cells, we found that four compounds (Dacomitinib, Cediranib, LY2835219, BGJ398) did not show toxicity to astrocyte cell and were efficacious to patient-derived GBM cells.

Indexed as

Antineoplastic AgentsAstrocytesCells, CulturedDrug Screening Assays, AntitumorGlioblastomaHigh-Throughput Screening AssaysHumansPrimary Cell CultureSpheroids, CellularAntineoplastic Agents

Identifiers

PMID34855773
PMCPMC8638871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.